Dr. Viviane S. Tabar, MD

Dr. Tabar practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Tabar's NPI, 1336123983, was assigned on December 6, 2005. Dr. Tabar graduated from American University of Beirut Faculty of Medicine in 1989. Dr. Tabar holds New York license 220652.

Dr. Tabar's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Tabar's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center (MSK), Department of Surgery. Dmand AI also links Dr. Tabar to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tabar practices, 2 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Tabar's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Tabar is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Tabar's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists craniotomy among the conditions Dr. Tabar treats.

CMS data shows 103 Medicare services from Dr. Tabar across 6 procedure codes in 2024, for 67 Medicare patients. Medicare paid $16,731 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 67 Medicare patients who saw Dr. Tabar in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tabar's median patient age at 68, with 56% women.

In 2017, Dr. Tabar wrote 13 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $128 in total drug cost. In 2016, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Tabar for performance year 2024, reported as part of a group. Dr. Tabar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tabar as offering telehealth.

Dmand AI links 137 papers to Dr. Tabar, published from 2003 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Brain Neoplasms, Cell Differentiation and Glioblastoma. Dr. Tabar has published most often in J Neurooncol. Dr. Tabar's most frequent co-authors are Cameron W. Brennan, MD, Kathryn Fp Beal, MD and Philip H. Gutin, MD.

CMS Open Payments shows 15 general payments to Dr. Tabar from 3 drug and device companies from 2018 to 2025. Acquisitions make up the largest share, 97% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $231,240.

Dmand AI lists 5 awards for Dr. Tabar, most recently Member in 2017.

Dr. Tabar graduated from American University of Beirut Faculty of Medicine in 1989. Dr. Tabar is a member of AANS, CNS, International Society for Stem Cell Research and New York Society for Neurosurgery.

Dr. Tabar is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.